Neurological Disorders Involving Neurons

Neurological Disorders Neurological disorders are diseases that affect the nervous system—either the brain, spinal cord, or peripheral nerves. These disorders can disrupt how neurons communicate, how muscles respond to commands, or how the brain processes information. In this section, we'll examine three important neurological disorders: Alzheimer's disease, Parkinson's disease, and myasthenia gravis. Understanding these conditions requires knowing how neurons normally function and how disruptions in that function lead to symptoms. Alzheimer's Disease Early Symptoms: Memory Loss Alzheimer's disease (AD) is a progressive neurodegenerative disorder that begins with changes in memory. The earliest and most distinctive hallmark of Alzheimer's disease is loss of short-term memory, which initially manifests as mild forgetfulness. A person might forget recent conversations, misplace everyday items, or struggle to remember what they ate for breakfast. This early memory loss is subtle and easy to dismiss, but it worsens progressively over time as more neurons in memory-related brain regions die. What makes this particularly important to recognize is that short-term memory loss appears before other symptoms become obvious, making it a critical early diagnostic indicator. Progression: Multiple Cognitive Domains As Alzheimer's disease progresses beyond the early stages, the damage spreads to other brain regions, affecting multiple domains of cognition. Three key impairments emerge: Language impairment (aphasia): Patients develop difficulty finding the right words, may speak in fragments, or have trouble understanding what others say to them. This isn't simply forgetfulness—it's a breakdown in the language systems of the brain. Impaired skilled movements (apraxia): Patients lose the ability to perform learned, purposeful movements despite having normal strength and sensation. For example, they may struggle to button a shirt or use a fork, even though their muscles work fine. Impaired object recognition (agnosia): Patients may see an object but not recognize what it is. For instance, they might look at a cup but not understand its purpose or even what they're looking at. Together, these three impairments—along with the earlier memory loss—reflect the widespread neuronal death characteristic of advancing Alzheimer's disease. Parkinson's Disease Primary Motor Symptoms Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. The disease manifests with several characteristic motor symptoms: Muscle rigidity: Muscles become stiff and resistant to movement, even at rest. This "lead pipe" rigidity can make simple movements like bending an arm feel effortful. Tremor: An involuntary shaking, often most noticeable in the hands. The tremor is typically present at rest and may diminish during intentional movement. Bradykinesia: Abnormally slowed movement. Patients move more slowly than normal, and initiating movement becomes difficult. Walking becomes shuffling, and fine motor tasks like writing become laborious. Akinesia: In severe cases, complete loss of movement occurs. This is the most debilitating form of movement impairment. The Neurochemical Basis Why do these motor symptoms occur? The answer lies in the brain chemistry underlying Parkinson's disease. The basal ganglia are brain structures that normally work with the motor cortex to control and initiate movement. This communication happens through a neurotransmitter called dopamine. In Parkinson's disease, dopaminergic neurons—the neurons that produce and release dopamine—degenerate and die. This leads to insufficient dopamine in the basal ganglia. When dopamine levels drop, the basal ganglia cannot properly stimulate the motor cortex. The result is reduced motor output: movements become slower (bradykinesia), muscles become rigid, and tremors emerge as the motor system struggles without proper dopamine signaling. In severe cases, when dopamine depletion is extreme, movement can cease entirely (akinesia). This neurochemical explanation is crucial because it directly informs treatment approaches for Parkinson's disease—therapies typically aim to restore dopamine levels or mimic dopamine's effects in the brain. Myasthenia Gravis Pathophysiology: Antibody-Mediated Neuromuscular Dysfunction Myasthenia gravis (MG) is an autoimmune disorder with a very different mechanism from Alzheimer's or Parkinson's disease. Rather than neuronal degeneration, myasthenia gravis involves the immune system attacking the neuromuscular junction—the specialized synapse where a motor neuron communicates with a muscle fiber. Here's what happens: The patient's immune system produces circulating antibodies (immune proteins) that specifically target acetylcholine receptors on the postsynaptic side of the neuromuscular junction. Acetylcholine is the neurotransmitter that normally binds to these receptors to trigger muscle contraction. When antibodies bind to or block these receptors, the acetylcholine released by the motor neuron cannot bind effectively. The result is fluctuating muscle weakness—a hallmark feature of myasthenia gravis. The weakness is "fluctuating" because: Antibody levels vary over time Repeated muscle use depletes acetylcholine stores further, worsening weakness Rest allows some recovery Muscle weakness tends to worsen as the day progresses (fatigability) This antibody-mediated destruction explains why myasthenia gravis is classified as an autoimmune disorder—the patient's own immune system is attacking their neuromuscular junctions. Treatment Approaches Because myasthenia gravis has a well-understood autoimmune mechanism, treatments target different points in the disease process: Immunosuppressants: These drugs reduce the overall activity of the immune system, decreasing antibody production and thereby reducing the attack on acetylcholine receptors. Examples include corticosteroids and other immunosuppressive agents. Cholinesterase inhibitors: These drugs work at the neuromuscular junction itself. They block the enzyme acetylcholinesterase, which normally breaks down acetylcholine after it's released. By preventing acetylcholine breakdown, these drugs increase the concentration of acetylcholine in the synaptic cleft, increasing the chance that remaining unfocused receptors will be activated. Common examples include pyridostigmine. Thymectomy: Surgical removal of the thymus gland. The thymus is an immune organ that, in some myasthenia gravis patients, contributes to antibody production against acetylcholine receptors. Thymectomy is particularly effective in younger patients and those with thymic abnormalities. This approach directly addresses a source of the pathogenic antibodies. These three treatment strategies reflect the flexibility of managing autoimmune neuromuscular disease—you can suppress the immune attack, boost the signaling that remains, or remove the source of antibody production.